Skip to main content
Journal cover image

Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis

Publication ,  Journal Article
Costa, LJ; Kramer, C; Hogan, KR; Butcher, CD; Littleton, AL; Shoptaw, KB; Kang, Y; Stuart, RK
Published in: Transfusion
November 2012

Plerixafor enhances the ability of filgrastim (FIL) to mobilize CD34+ cells but adds cost to the mobilization. We hypothesized that replacing weight‐based FIL with flat‐dose pegfilgrastim (PEG) in a validated cost‐based mobilization algorithm for patient‐adapted use of plerixafor would add convenience without increased cost. A single‐center retrospective analysis compared two consecutive cohorts undergoing FIL or PEG mobilization before autologous hematopoietic stem cell transplantation for multiple myeloma or lymphoma. FIL dose was 10 µg/kg/day continuing until completion of collection and a 12‐mg flat dose of PEG. Peripheral blood CD34+ cells (PB‐CD34+) enumeration was performed on the fourth day after initiation of growth factor. Subjects surpassing a certain target‐specific threshold of PB‐CD34+ started apheresis immediately while subjects with lower PB‐CD34+ received plerixafor with apheresis starting on the fifth day. Overall 68 of 74 in the FIL group and 52 of 57 patients in the PEG group met the mobilization target. Only one patient in each cohort required remobilization. Median PB‐CD34+ on Day 4 was significantly higher in patients in the PEG group (18.1 × 10 vs. 28.7 × 10 cells/L, p = 0.01). Consequently, patients in the PEG group were less likely to require administration of plerixafor (67.5% vs. 45.6%, p = 0.01). Cohorts had near identical mean number of apheresis sessions and comparable CD34+ yield. The estimated cost associated with growth factor was higher in patients in the PEG group, but it was counterbalanced by lower cost associated with use of plerixafor. Single administration of 12 mg of PEG is associated with better CD34+ mobilization than FIL allowing for effective, convenient mobilization with less frequent use of plerixafor.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Transfusion

DOI

EISSN

1537-2995

ISSN

0041-1132

Publication Date

November 2012

Volume

52

Issue

11

Start / End Page

2375 / 2381

Publisher

Wiley

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Costa, L. J., Kramer, C., Hogan, K. R., Butcher, C. D., Littleton, A. L., Shoptaw, K. B., … Stuart, R. K. (2012). Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion, 52(11), 2375–2381. https://doi.org/10.1111/j.1537-2995.2012.03579.x
Costa, Luciano J., Cindy Kramer, Kathy R. Hogan, Coleen D. Butcher, Amanda L. Littleton, Katie B. Shoptaw, Yubin Kang, and Robert K. Stuart. “Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.” Transfusion 52, no. 11 (November 2012): 2375–81. https://doi.org/10.1111/j.1537-2995.2012.03579.x.
Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, et al. Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 2012 Nov;52(11):2375–81.
Costa, Luciano J., et al. “Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.” Transfusion, vol. 52, no. 11, Wiley, Nov. 2012, pp. 2375–81. Crossref, doi:10.1111/j.1537-2995.2012.03579.x.
Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK. Pegfilgrastim‐ versus filgrastim‐based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. Wiley; 2012 Nov;52(11):2375–2381.
Journal cover image

Published In

Transfusion

DOI

EISSN

1537-2995

ISSN

0041-1132

Publication Date

November 2012

Volume

52

Issue

11

Start / End Page

2375 / 2381

Publisher

Wiley

Related Subject Headings

  • Cardiovascular System & Hematology
  • 3204 Immunology
  • 3202 Clinical sciences
  • 3201 Cardiovascular medicine and haematology
  • 1107 Immunology
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology